Please login to the form below
EGFR-mutation
This page shows the latest EGFR-mutation news and features for those working in and with pharma, biotech and healthcare.
Takeda’s Exkivity receives NICE recommendation for rare form of lung cancer
mutation-positive (Exon20ins+) advanced non-small cell lung cancer (NSCLC), who have already received platinum-based chemotherapy. ... Patients with EGFR Exon20ins+ NSCLC make up approximately 2% of patients with NSCLC.
Latest news
-
AZ’s Tagrisso cuts risk of EGFR-positive NSCLC spreading to the brain
Results showing EGFR-inhibitor improves outcomes in adjuvant setting released at ESMO 2020 virtual congress. ... Approximately a quarter of global lung cancer cases are EGFR-mutated, although in Asia the rate can climb to over 40% of new cases.
-
J&J’s bispecific lung cancer antibody nabs FDA breakthrough status
This type of mutation occurs in tumours that aren’t sensitive to treatment with first- and second-generation small-molecule EGFR inhibitors like AstraZeneca’s Iressa (gefitinib), Roche’s Tarceva (erlotinib) ... Last year, Spectrum Pharmaceuticals
-
Roche’s Tecentriq/Avastin combo improves survival in liver cancer
The Tecentriq/Avastin combination is already approved for non-squamous non-small cell lung cancer (NSCLC) without EGFR or ALK mutations, and as a triple therapy with chemotherapy for EGFR or ... ALK mutation-positive non-squamous NSCLC.
-
Roche eyes filings for Tecentriq/Avastin combo in liver cancer
The duo has already been approved for non-squamous non-small cell lung cancer (NSCLC) without EGFR or ALK mutations, and as a triple therapy with chemotherapy for EGFR or ALK ... mutation-positive non-squamous NSCLC, making it the only checkpoint
-
AstraZenca to appeal NICE rejection of Tagrisso
The drug is licensed in untreated locally-advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive NSCLC in the EU. ... NICE agreed that Tagrisso extends progression-free (PFS) and overall survival (OS) compared with first
More from news
Approximately 2 fully matching, plus 51 partially matching documents found.
Latest Intelligence
-
China: AstraZeneca’s new engine for growth and innovation
There is a good reason why Tagrisso was chosen for the fast track – the drug is for patients with epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung ... The EGFR mutation is particularly prevalent in Asian populations
-
Harnessing complexity
While more established methodologies still dominate, Next Generation Sequencing is starting to make an impact in the Oncology CDx world, as this breakdown of methodologies used for EGFR mutation testing in
-
Transforming times at AstraZeneca
It is a particularly pressing matter for AZ considering the company has several personalised medicines on market or in development, including Iressa (gefitinib) to treat lung cancer patients with a mutation ... in the EGFR-TK gene and Lynparza, which is
-
Diagnostics are rising up the pharma value chain
lung cancer, which was backed together with Roche Diagnostics' cobas EGFR Mutation Test. ... He adds: “What do we do when a person says they have a mutation of this type of cancer and there seems to be a drug.
-
Interview: AstraZeneca's Susan Galbraith
If approved, the drug would complement AZ's other NSCLC drug, Iressa, which is approved in NSCLC patients with the EGFR mutation. ... Another development is AZD9291 – a drug which addresses the T790M mutation, which is a key resistance mechanism to
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest from PMHub
-
September 2020: diversity and inclusion in clinical trials round-up
EGFR mutation frequencies vary in LATAM countries, and studies have suggested that somatic mutation frequency in EGFR in lung cancer could be associated with genetic ancestry.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Sanofi's frexalimab shows promise in relapsing forms of MS
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- Amgen reports positive results for Otezla in psoriatic arthritis
- Supply chain challenges in 2023
- Whitepaper: Closing the gap with compelling healthcare communications
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Supporting the most vulnerable: why pharma should get behind the NHS’ healthcare equity campaign
- Healing the Healers
- The (inevitable) digital transformation of Medical Affairs
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
No results were found
PMHub
Branding Science
We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...
Latest intelligence
- Whitepaper: Closing the gap with compelling healthcare communications
- Want to learn how to close the distance between a person’s current health and their healthiest possible self?...
- Healing the Healers
- Because if we do not heal the healers, who is going to heal us?...
- The (inevitable) digital transformation of Medical Affairs
- It’s not a question of ‘if,’ it’s a question of ‘when.’...
